Ruth Halaban
Has grant
Senior Research Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Targeted Therapy of Melanoma with LZTR1 and CRKL inhibitors
Open Date: 2021-06-01
Close Date: 2024-05-31
Grant: Close
MRA Team Award
Open Date: 2018-06-01
Close Date: 2021-05-01
Grant: Close
Patient Focused Therapy for Acral Melanoma
Open Date: 2018-06-01
Close Date: 2021-09-30
Articles (5)
Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide–induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting nitrosylation sensitized NRAS-mutant melanomas to targeted MEK inhibitors (MEKi), leading to sustained downregulation of the ERK-MAPK pathway, along with concomitant denitrosylation of NRAS, MEK, ERK, RSK1, and DUSPs. Global nitrosylome profiling using mass spectrometry revealed nitrosylation of multiple ERK regulators. Gain- and loss-of-function studies confirmed a positive association between nitrosylation and ERK activation. ERK and MEK proteins harbored potential nitrosylation sites, mutation of which abrogated their phosphorylation and inhibited cell growth. The nitrosylome also contained damage-associated molecular patterns (DAMP), factors known to induce immunogenic cell death (ICD). Notably, nitrosylation inhibition combined with MEKi markedly inhibited NRAS-mutant melanoma growth in an immunocompetent mouse model. This was accompanied by downregulated MEK-ERK signaling and extracellular release of DAMPs such as calreticulin, phospho-eIF2α, and HMGB1, confirming ICD induction. Furthermore, the combination significantly increased the repertoire of CD8+ T cells, dendritic cells, and macrophages in the tumor microenvironment, which was validated in cocultures of dendritic cells and T lymphocytes. In conclusion, the current study demonstrates that nitrosylation inhibition sensitizes NRAS-mutant melanomas to targeted MEKi-induced cell death and causes the release of non-nitrosylated (active) DAMPs that induce a potent antimelanoma immune response via ICD. These findings highlight potential therapeutic vulnerabilities in the currently untreatable NRAS-mutant melanoma subtype. Significance: Nitrosylation-regulated molecular mechanisms present a vulnerability that can be exploited to sensitize NRAS-mutant melanomas to existing targeted therapies while enhancing antitumor immunity.
Year:
2025
Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide–induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting nitrosylation sensitized NRAS -mutant melanomas to targeted MEK inhibitors (MEKi), leading to sustained downregulation of the ERK-MAPK pathway, along with concomitant denitrosylation of NRAS, MEK, ERK, RSK1, and DUSPs. Global nitrosylome profiling using mass spectrometry revealed nitrosylation of multiple ERK regulators. Gain- and loss-of-function studies confirmed a positive association between nitrosylation and ERK activation. ERK and MEK proteins harbored potential nitrosylation sites, mutation of which abrogated their phosphorylation and inhibited cell growth. The nitrosylome also contained damage-associated molecular patterns (DAMP), factors known to induce immunogenic cell death (ICD). Notably, nitrosylation inhibition combined with MEKi markedly inhibited NRAS -mutant melanoma growth in an immunocompetent mouse model. This was accompanied by downregulated MEK-ERK signaling and extracellular release of DAMPs such as calreticulin, phospho-eIF2α, and HMGB1, confirming ICD induction. Furthermore, the combination significantly increased the repertoire of CD8 + T cells, dendritic cells, and macrophages in the tumor microenvironment, which was validated in cocultures of dendritic cells and T lymphocytes. In conclusion, the current study demonstrates that nitrosylation inhibition sensitizes NRAS -mutant melanomas to targeted MEKi-induced cell death and causes the release of non-nitrosylated (active) DAMPs that induce a potent antimelanoma immune response via ICD. These findings highlight potential therapeutic vulnerabilities in the currently untreatable NRAS -mutant melanoma subtype. Significance: Nitrosylation-regulated molecular mechanisms present a vulnerability that can be exploited to sensitize NRAS -mutant melanomas to existing targeted therapies while enhancing antitumor immunity.
Year:
2025
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technology that enables genome-wide error correction at single read-level, achieving an error rate of 4.2 × 10 −7 , which is about two orders of magnitude lower than a read-centric de-noising method. The application of AccuScan to MRD demonstrated analytical sensitivity down to 10 −6 circulating variant allele frequency at 99% sample-level specificity. AccuScan showed 90% landmark sensitivity (within 6 weeks after surgery) and 100% specificity for predicting relapse in colorectal cancer. It also showed 67% sensitivity and 100% specificity in esophageal cancer using samples collected within one week after surgery. When AccuScan was applied to monitor immunotherapy in melanoma patients, the circulating tumor DNA (ctDNA) levels and dynamic profiles were consistent with clinical outcomes. Overall, AccuScan provides a highly accurate WGS solution for MRD detection, empowering ctDNA detection at parts per million range without requiring high sample input or personalized reagents.
Year:
2024
Effective anti-tumor immunity is largely driven by cytotoxic CD8 + T cells that can specifically recognize tumor antigens. However, the factors which ultimately dictate successful tumor rejection remain poorly understood. Here we identify a subpopulation of CD8 + T cells which are tumor antigen-specific in patients with melanoma but resemble KIR + CD8 + T cells with a regulatory function (Tregs). These tumor antigen-specific KIR + CD8 + T cells are detectable in both the tumor and the blood, and higher levels of this population are associated with worse overall survival. Our findings therefore suggest that KIR + CD8 + Tregs are tumor antigen-specific but uniquely suppress anti-tumor immunity in patients with melanoma.
Year:
2024
Year:
2023
Collaborators (10)
Qin Yan
Anthony N. Brady Professor of Pathology
Yale University
David Chen
Assistant Professor
Washington University in Saint Louis School of Medicine
Yuval Kluger
Yale University
Mario Sznol
Professor of Clinical
University of Miami
SANJAY PREMI
Assistant Professor
H Lee Moffitt Cancer Center and Research Institute
David Hafler
Professor
Yale University
Benjamin Lu
Yale University
Paulo Rodriguez
Senior Member-Professor
H Lee Moffitt Cancer Center and Research Institute
Mohammed Abuul Usmani
Senior Scientist
Washington University in St. Louis
Kenneth Tsai
Vice Chair of Research, Senior Member
H Lee Moffitt Cancer Center and Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.